Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
2.
Australas J Dermatol ; 59(4): 315-317, 2018 Nov.
Article in English | MEDLINE | ID: mdl-29572811

ABSTRACT

OBJECTIVES: To conduct an audit of teledermatologist expert skin advice, a store and forward tele-dermatological service, to determine its effectiveness and user satisfaction in managing cutaneous adverse drug reactions in patients with hepatitis C, and to demonstrate a unique collaborative model of care for patients receiving specialised drug therapy. METHODS: A retrospective analysis of data on teledermatologist expert skin advice referrals from January 2014 to December 2015 was performed. The primary outcomes assessed included number of referrals, referral locations, diagnoses, response times, quality of clinical information provided and user satisfaction ratings. RESULTS: Altogether 43 consultations from 29 referring sites were received from Australian metropolitan and rural settings. Of the patients, 43 were diagnosed with an adverse drug reaction related to the use of either telaprevir or simeprevir. The average time taken for the dermatologist to reply electronically with a final diagnosis and management plan was 1 h 57 min. As many as 26% of referrals required additional photos to establish a diagnosis due to poor-quality images or insufficient detail. Altogether 18 clinicians completed the customer satisfaction survey, all of whom rated teledermatologist expert skin advice nine or above on a scale of one to 10. CONCLUSIONS: Teledermatologist expert skin advice was regarded by clinicians as a valuable patient care service. The platform is a novel modality that supports patients undergoing specialised treatments at risk of cutaneous adverse drug reaction.


Subject(s)
Dermatology/methods , Drug Eruptions/diagnosis , Telemedicine/methods , Antiviral Agents/adverse effects , Attitude of Health Personnel , Drug Eruptions/etiology , Drug Eruptions/therapy , Female , Hepatitis C/drug therapy , Humans , Male , Medical Audit , Middle Aged , Oligopeptides/adverse effects , Retrospective Studies , Simeprevir/adverse effects , Telemedicine/organization & administration , Time Factors
3.
Australas J Dermatol ; 57(1): 14-8, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26559493

ABSTRACT

OBJECTIVE: To conduct an audit of the Skin Emergency Telemedicine Service at Princess Alexandra Hospital in Brisbane from January to December 2014, and determine whether there has been any change in the number, type and location of referrals. METHODS: Retrospective analyses of referrals to the teledermatology service were conducted and compared with the 2012 audit. Main outcomes assessed included the number of referrals, referral site location, telediagnosis categories, image characteristics and response times. RESULTS: In 2014, 318 cases were referred to the teledermatology service. The highest number of cases (n = 140) were referred from Princess Alexandra Hospital and Queen Elizabeth II Jubilee Hospital emergency departments. However, referrals to the teledermatology service came from as far as 1600 km distant from Brisbane. The most common provisional telediagnoses were dermatitis or eczema, skin infection or drug eruption. Over half of all referrals (62%) received a response within 3 h and a further 20% were responded to within 3-6 h. Almost half all referring doctors (48%) attached very large image files (> 500 kb) to their referral. CONCLUSIONS: The Skin Emergency Telemedicine Service has proved to be a successful, sustainable and valuable addition to the specialist dermatology services provided across Queensland. With adequate funding and resources and appropriate attention to ethical and legal considerations, our service could significantly change the management of Queenslanders with acute skin conditions.


Subject(s)
Dermatology/trends , Referral and Consultation/statistics & numerical data , Skin Diseases/diagnosis , Telemedicine/trends , Australia , Dermatology/methods , Emergencies , Emergency Service, Hospital/statistics & numerical data , Humans , Photography , Retrospective Studies , Time Factors
4.
Int J Dermatol ; 48(11): 1236-45, 2009 Nov.
Article in English | MEDLINE | ID: mdl-20064185

ABSTRACT

BACKGROUND: Data suggest that photodynamic therapy using topical methyl aminolevulinate (MAL PDT) may be a noninvasive alternative to excisional surgery for nodular basal cell carcinoma (BCC). In the studies described here, we investigated the histologic response, tolerability, and cosmetic outcome with MAL PDT for primary nodular BCC (or= 50% reduction in greatest diameter) at 3 months were re-treated (21%). Treatment sites were excised at 3 months (clinical nonresponders) or 6 months (clinical responders) after the last treatment. RESULTS: Histologically verified lesion complete response rates were higher with MAL PDT than with placebo [73% (55/75) vs. 27% (20/75)]. Treatment was most effective for facial lesions (89% complete response). Cosmetic outcome was good or excellent in 98% of evaluable, completely responding lesions treated with MAL PDT. CONCLUSION: Although longer follow-up studies are required, these promising data indicate the potential of topical MAL PDT as a noninvasive treatment alternative for nodular BCC.


Subject(s)
Aminolevulinic Acid/analogs & derivatives , Carcinoma, Basal Cell/drug therapy , Photochemotherapy/methods , Photosensitizing Agents/therapeutic use , Skin Neoplasms/drug therapy , Adult , Aged , Aged, 80 and over , Aminolevulinic Acid/adverse effects , Aminolevulinic Acid/therapeutic use , Carcinoma, Basal Cell/pathology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Photochemotherapy/adverse effects , Photosensitizing Agents/adverse effects , Prospective Studies , Skin Neoplasms/pathology , Treatment Outcome
5.
Australas J Dermatol ; 49(4): 220-2, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18855785

ABSTRACT

A 22-year-old woman presented with recurrent non-ulcerating skin nodules overlying the great saphenous vein on the anteromedial lower legs. Histology showed a granulomatous phlebitis, and polymerase chain reaction performed on lesional skin detected DNA specific for Mycobacterium tuberculosis. The lesions resolved with anti-tuberculous therapy. This case may be a further example of nodular granulomatous phlebitis, a phlebitic tuberculid.


Subject(s)
Granuloma/diagnosis , Granuloma/etiology , Phlebitis/diagnosis , Phlebitis/etiology , Tuberculosis, Cutaneous/complications , Tuberculosis, Cutaneous/diagnosis , Adult , Antitubercular Agents/therapeutic use , Diagnosis, Differential , Female , Granuloma/drug therapy , Granuloma/microbiology , Humans , Isoniazid/therapeutic use , Mycobacterium tuberculosis/isolation & purification , Panniculitis/diagnosis , Phlebitis/drug therapy , Phlebitis/microbiology , Rifampin/therapeutic use , Treatment Outcome , Tuberculosis, Cutaneous/drug therapy , Tuberculosis, Cutaneous/microbiology
6.
Australas J Dermatol ; 43(4): 241-6, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12423429

ABSTRACT

The finding of mutations in the PTCH gene in both Gorlin's syndrome and sporadic basal cell carcinomas has significantly advanced our understanding of the molecular defects that lead to the formation of these tumours. Knowledge of the specific molecular and functional changes that have taken place in these tumours will help us devise more defined therapies, as well as give us a better understanding of normal molecular pathways involved in skin development and function. The following is a summary of our current understanding of the molecular and cellular biology of basal cell carcinoma.


Subject(s)
Carcinoma, Basal Cell/genetics , Skin Neoplasms/genetics , Apoptosis/physiology , Carcinoma, Basal Cell/physiopathology , Humans , Membrane Proteins/genetics , Membrane Proteins/physiology , Patched Receptors , Patched-1 Receptor , Proto-Oncogene Proteins c-bcl-2/physiology , Receptors, Cell Surface , Skin Neoplasms/physiopathology , Transforming Growth Factor beta/genetics , Transforming Growth Factor beta/physiology , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/physiology , fas Receptor/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...